Drug intelligence / Profile preview

TLM-008

Development stage: Preclinical
Lead developer: TLM

Overview

**TLM-008** is an unnamed preclinical Therillume pipeline candidate being developed for **glioblastoma multiforme**. Publicly available pipeline information identifies it only by the internal code **TLM-008**, lists **TLM** as the developer, and places the program at the **preclinical** stage for GBM. No validated public details were found on its molecular target, precise mechanism of action, modality, dosage form, route of administration, or manufacturing arrangements, so it should currently be treated as a confidential early-stage oncology asset rather than a fully characterized drug candidate.

Beyond the preview

Go deeper on TLM-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLM-008.

Explore the full profile